deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03167255

Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

Sponsor: Cooperative International Neuromuscular Research Group

Conditions Duchenne Muscular Dystrophy
Interventions NS-065/NCNP-01
Updated 20 times since 2017 Last updated: Dec 1, 2022 Started: Jul 6, 2017 Primary completion: Oct 20, 2021 Completion: Nov 15, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03167255, this PHASE2 trial focuses on Duchenne Muscular Dystrophy and remains completed. Sponsored by Cooperative International Neuromuscular Research Group, it has been updated 20 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Jan 2018 · 3 months · monthly snapshot~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Apr 2019 · 5 months · monthly snapshot~Apr 2019 – ~May 2020 · 13 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Feb 2025 — Sep 2025 [monthly]

    Completed PHASE2

  3. Sep 2024 — Feb 2025 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. Feb 2023 — Jul 2024 [monthly]

    Completed PHASE2

▶ Show 15 earlier versions

  1. Jan 2023 — Feb 2023 [monthly]

    Completed PHASE2

  2. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  3. Dec 2021 — Dec 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Sep 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  5. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE2

  7. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Apr 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Enrolling By Invitation → Active Not Recruiting

  9. Nov 2018 — Apr 2019 [monthly]

    Enrolling By Invitation PHASE2

  10. Jun 2018 — Nov 2018 [monthly]

    Enrolling By Invitation PHASE2

  11. Feb 2018 — Jun 2018 [monthly]

    Enrolling By Invitation PHASE2

  12. Jan 2018 — Feb 2018 [monthly]

    Enrolling By Invitation PHASE2

  13. Oct 2017 — Jan 2018 [monthly]

    Enrolling By Invitation PHASE2

  14. Sep 2017 — Oct 2017 [monthly]

    Enrolling By Invitation PHASE2

    Status: Not Yet Recruiting → Enrolling By Invitation

  15. Jun 2017 — Sep 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cooperative International Neuromuscular Research Group
  • NS Pharma, Inc.
  • Nippon Shinyaku Co., Ltd.
  • Therapeutic Research in Neuromuscular Disorders Solutions
Data source: NS Pharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations